{"text": "A study on risperidone found that obese patients had similar treatment\n\nresponse rates compared to non-obese patients (Kaplan et al., 2017). However,\n\nanother study on aripiprazole reported lower efficacy in obese patients\n\ncompared to non-obese patients.\n\nPharmacokinetics and Efficacy in Obese Patients\n\nObesity is a growing concern worldwide, affecting approximately 39% of\n\nadults in the United States (CDC). The impact of weight on antipsychotic", "embedding": []}